You are on page 1of 3

38

DAFTAR PUSTAKA

1. Sonneveld P, Schmidt-Wolf IGH, Holt BVD, Jarari LE, Bertsch U,
Salwender H, et al. Bortezomib induction and maintenance treatment in
patients with newly diagnosed multiple myeloma: results of the
randomized phase III HOVON-65/GMMG-HD4 trial. J Clin Oncol
2012;30:2946-55.
2. Rosinol L, Oriol A, Teruel AI, Hernandez D, Lopez-Jiminez J,Rubla JDL,
et al. Superiority of bortezomib, thalidomid, and dexamethasone (VTD) as
induction pretransplantation therapy in multiple myeloma: a randomized
phase 3 PETHEMA/GEM study. Blood 2012;120(8):1589-96.
3. Cavo M, Tacchetti P, Patriarca F, Petrucci MT, Pantani L, Galli M, et al.
Bortezomib with thalidomid plus dexamethasone compared with
thalidomide plus dexamethasone as induction therapy before, and
consolidation therapy after, double autologous stem-cell transplantation in
newly-diagnosed multiple myeloma: arandomised phase 3 study. Lancet
2010;376:2075-85.
4. Palumbo A, Bringhen S, Rossi D,Cavalli M, Larocca A, Ria R, et. al.
Bortezomib-melphalan-prednisone-thalidomide followed by maintenance
with bortezomib-thalidomide compared with bortezomib-melphalan-
prednisone for initial treatment of multiple myeloma: a randomized
controlled trial. J Clin Oncol 2010;28:5101-9.
5. Mateos M-V, Oriol A, Lopez JM, Teruel AI, Guia ALDL, Lopez J, et al.
GEM 2005 trial update comparing VMP/VTP as induction in elderly
multiple myeloma patients: do we still need alkylators? Blood
2014;124912):1887-93.
6. Hulin C, Facon T, Rodon P, Pegourie B, Benboubker L, Doyen C, et al.
Efficacy of melphalan and prednisone plus thalidomide in patients older
than 75 years with newly diagnosed multiple myeloma : IFM 01/01 trial. J
Clin Oncol. 2009;22:3664-70.
7. Fayers PM, Palumbo A, Hulin C, Waage A, Wijermans P, Beksaç M, et al.
Thalidomide for previously untreated elderly patients with multiple
myeloma: meta-analysis of 1685 individual patient data from 6
randomized clinical trials. Blood. 2011;118:1239-47.

Kim K. Reksodiputro AH. Rajkumar SV. Genadieva-Stavric S.32:1-17. New York: Mc Graw Hill. et al. 18. . and outcome in multiple myeloma patients in different geographical areas of the world. Kim JS. Myeloma. Patel P. Min CK. Blood 2011.1645-81. et al. Palumbo A.p. 2014. Indonesian J Cancer. 16. Blade J. 2013.1(28):3-11. New approaches to management of multiple myeloma. Moraeu P. N Engl J Med. Rhee FV. Tadjoedin H. Yoon SS. et al.15(2):157- 70. Anaissie E. Registrasi Kanker Rumah Sakit Kanker Dharmais tahun 1993-2010. 8th ed. Clinical profiles of multiple myeloma in Asia-An Asian Myeloma Network study. Supandiman I. Cavallo F. Angtuaco E. Nair B. Prchal JT. 9. International Myeloma Working Group consensus statement for the management. Thalidomide-dexamethasone compared with melphalan-prednisolone in elderly patients with multiple myeloma. In: Kaushansky K. Cavo M. et al. 17. Kipps TJ.11(23):6063-73.113:3435–3442. Toruan T. Lichtman MA. Palumbo A. Kyle RA. Morgan G. Shimizu K. Curr Treat Opt Oncol 2014. J Adv Intern Med 2012. J Clin Oncol. 12. Seligsohn U. 13. Williams Hematology. 15. and supportive care for myeloma patients who are not eligible for standard autologous stem-cell transplantation. Larocca A.351:1860-73. Oman Med J. Hajek R. Drug therapy multiple myeloma. 2004. Saraf S. Ludwig H. Sumantri R. editors. Lee JH. Sinuraya ES. Multiple myeloma in Indonesia. 2011. Epidemiology. International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem-cell transplantation. Niezvizky R. biology. Multiple myeloma : An update. 2010. Rajkumar SV. Beuler E. Al-Farsi K. 2014. 11. Kosasih AA. 14.89:751-6.01:20-32. et al. Rajkumar SV. treatment. Bartel T. 39 8. Epstein J. 10. Orlowski R. Palumbo A. Tóthová E et al.2(5):76-81. Rondelli D. Am J Hematol. Blood 2009. San Miguel JF.

Wijermans P. Mink PJ. 2011. Alexander DD. Larocca A. Asian Pac J Cancer Prev. Ozasa K. Haematologica 2013. Buadi FK. Hayman SR. Hwang SY. Adami HO. et al. Lacy MQ. Larocca A. 2014. 23. Chang X. Multiple Myeloma. Zhu Y. Mori Mitsuru. Facon T. et al. Int J Cancer. Durie BGM. Zweegman S.14:571-9. Oken MM. Improved survival in multiple myeloma and the impact of novel therapies. 2006. Stewart AK. . Barlogie B. Sakauchi Fumio. 2015. Matsuo K. Kumar SK. Age and organ damage correlate with poor survival in myeloma patients: Meta-analysis of 1435 individual patient data from 4 randomized trials. International uniform response criteria for multiple myeloma. 20. Gay F. Schaafsma R. J Clin Oncol. 26. and the impact of novel agents. Anderson K. Rossi D. Giralt S. Mechanism of immunomodulatory drugs’ action in the treatment of multiple myeloma. 24. Multiple myeloma: a review of the epidemiologic literature.364:1046-60. Leukemia. Shi C.98:980-7. Acta Biochim Biophys Sin. Cavallo F.46(3):240-7. Moreau P. Falcone AP. Chanan-Khan AA. et al. Attal M. 2007. et al. Mandel JS. 2006. Oriol A.120 Suppl 12:40-61. Chim CS. 27. Tan D. 22. Chng WJ. Anderson K.117:3025-31. Miguel JS. Frontline therapy of multiple myeloma. 2006. Chou T. Tamakoshi A. Management of multiple myeloma in Asia: resource-startified guidelines. Palumbo A.20:3076-84.5(111):2516-20. 40 19. et al.15(28):2612-24. Risk factor for multiple myeloma: Evidence from the Japan Collaborative Cohort (JACC) Study. Harousseau JL. Lancet 2013.20:1467-73. Blood. Blood. Dispenzieri A. 2010.7:575-81 21. Rajkumar SV. 25. Nawarawong SY. 2008. Mateos MV. et al. Importance of achieving a complete response in multiple myeloma. Bringhen S. Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patients. Blade J. N Engl J Med 2011. Cole P. Blood. 28. 29. Khan MM.